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AObjective: Pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hyper-
tension. In many patients hemodynamics are normalized early after surgical intervention. However, the effect of
residual pulmonary hypertension on postoperative clinical status and survival is unknown.
Methods: Data were collected prospectively on all patients who underwent pulmonary endarterectomy in a con-
tinuous national series between 1997 and December 2007. Postoperatively, patients underwent scheduled rein-
vestigation, including functional testing and right heart catheterization, at 3 months after the operation. They
were divided into 2 groups based on mean pulmonary artery pressure: group 1, less than 30 mm Hg; group 2,
30 mm Hg or greater.
Results: Three hundred fourteen patients underwent pulmonary endarterectomy, survived to hospital discharge,
and completed the 3-month follow-up period. At 3 months after pulmonary endarterectomy, there was a signifi-
cant reduction in mean pulmonary artery pressure for the whole cohort (48  12 to 26  10 mm Hg, P< .001).
However, 31% of the patients had residual pulmonary hypertension. Group 1 patients enjoyed significantly better
exercise capacity and improved symptoms compared with group 2 patients. In addition, there were significantly
fewer patients receiving targeted medical therapy in group 1 versus group 2 (0% vs 25%, P<.001). Conditional
survival after discharge from the hospital for the whole cohort was 90.0% at 5 years and was not different between
groups (90.3% for group 1 vs 89.9% for group 2, P ¼ .36).
Conclusions: For patients undergoing pulmonary endarterectomy, survival after hospital discharge is excellent.
Residual pulmonary hypertension significantly compromised symptom status and functional capacity but did not
appear to adversely affect medium-term survival. The effect of targeted medical therapy in patients with residual
pulmonary hypertension after pulmonary endarterectomy needs to be evaluated further. (J Thorac Cardiovasc
Surg 2011;141:383-7)Chronic thromboembolic pulmonary hypertension
(CTEPH) is a serious condition. Historically before the de-
velopment of surgical treatment, survival was very poor.1
In a recent cohort of patients comprehensively followed in
the modern era, outcomes had improved.2 Pulmonary endar-
terectomy is the treatment of choice to relieve pulmonary
artery obstruction in patients with CTEPH and has been re-
markably successful.3 The largest and most comprehensive
series to date demonstrates that in the postoperative period
patients enjoy a reduction in pulmonary pressure and an im-
provement in cardiac function with few complications and
a low risk of mortality.4e Department of Cardiothoracic Surgery and Pulmonary Vascular Diseases
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The Journal of Thoracic and CaHowever, not all patients are suitable for surgical inter-
vention, and it is increasingly recognized that some patients
have residual pulmonary hypertension (PH) after pulmonary
endarterectomy.5-7 Estimates of the number of patients with
residual PH after pulmonary endarterectomy have varied
from 5% to 35% depending on the definition, and few
units have evaluated these patients comprehensively. One
other center has reported post–pulmonary endarterectomy
persistent PH, with an incidence of 35% (33/93 patients)
at 1 year.5 Another center recently reported a 24% incidence
of increased pulmonary vascular resistance (PVR) after pul-
monary endarterectomy and showed that advanced New
York Heart Association (NYHA) class was associated
with poorer survival.8 When we reported all incident cases
of CTEPH in the United Kingdom between 2001 and
2006, we found that in 198 patients investigated at 3 months
after pulmonary endarterectomy, using the formal definition
of PH (mean pulmonary artery pressure [mPAP]>25 mm
Hg and PVR>240 dynes $ sec1 $ cm5 at rest), residual
PH was present in 35%.2 To our surprise, survival at 3 years
remained excellent and was not different from that of the
larger group with no residual PH. In the past, medical man-
agement of patients with CTEPH has proved disappointing,rdiovascular Surgery c Volume 141, Number 2 383
Abbreviations and Acronyms
CTEPH ¼ chronic thromboembolic pulmonary
hypertension
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Dwith little response to vasodilator therapy.9,10 However,
newer targeted medical therapies might provide some
advantage, and therefore it is important to identify patients
who could benefit from medical treatment even after
pulmonary endarterectomy surgery.11-16
Many units have now reported in-hospital results after
pulmonary endarterectomy surgery. Outcome after discharge
from the hospital has been more difficult to quantify and less
frequently reported. We have recently published the results of
pulmonary endarterectomy surgery after hospital discharge
for all United Kingdom patients.2,17 Even though this series
included patients from the beginning of our pulmonary
endarterectomy program, we found remarkable improvement
in functional and hemodynamic parameters at 3 months and
1 year, with excellent medium-term survival at 5 years.
However, the CTEPH disease process is complex, and it is
known that patients with operable (so-called proximal) dis-
ease in the segmental pulmonary artery branches can also
have a distal small-vessel vasculopathy in the nonobstructed
vascular beds with histologic changes similar to those seen
in idiopathic PH.18,19 Indeed, this 2-compartment model
was proposed many years ago by Moser and Braunwald20
after their early experience of treating this condition. This
fact explains why some patients have a degree of persisting
PH even after apparently successful surgical clearance of all
visible disease. Persistently increased PVR in the immediate
postoperative period is known to be a significant risk factor
for in-hospital death, especially if greater than 500 dynes $
s1 $ cm5.2,4 The effect of residual PH in the longer term
is not completely understood. The objective of this study
was to determine the effect of residual PH on symptom
status and survival after pulmonary endarterectomy in the
largest cohort followed to date.
MATERIALS AND METHODS
All patients with CTEPHwere discussed preoperatively at a weekly mul-
tidisciplinary team meeting with PH physicians, specialist radiologists, and
pulmonary endarterectomy surgeons. All data were entered prospectively
into a dedicated surgical and PH database, as previously reported.17 An in-
ferior vena caval filter was inserted in all patients preoperatively. Pulmonary
endarterectomy was performed by using principles similar to those used by
the University of California, San Diego group.4,21 All patients underwent
surgical intervention with deep hypothermia, but complete arrest of the
circulation was not used in every case.17,22 Anticoagulation was
continued postoperatively in all cases.384 The Journal of Thoracic and Cardiovascular SurgAt 3 months after pulmonary endarterectomy, all patients were invited to
return to Papworth Hospital for full review by the pulmonary vascular disease
physicians. NYHA class, 6-minute walk test, and right heart catheterization
data were recorded. These variables were again examined at 12 months after
pulmonary endarterectomy, although right heart catheterization was not
repeated unless there was residual PH at 3 months or changes in symptom
status, echocardiographic estimates of pulmonary artery pressure, or both.
Patients continued follow-up at their local PH specialist center after 1 year.
Based on the mPAP at 3 months, patients were divided into 2 groups:
those with mPAPs of less than 30 mm Hg (group 1) and those with poten-
tially prognostically important post–pulmonary endarterectomy PH mPAPs
of 30 mmHg or greater (group 2). Thirty millimeters of mercury was chosen
as the division because pressures of greater than and less than this level at
baseline appeared to correlate with impaired or normal survival in Riedel
and colleagues’ original account of survival in patients with CTEPH.1 It
was also a more useful practical definition of residual PH in patients after
pulmonary endarterectomy because it coincided with the pressure criteria
accepted in our hospital above which to consider use of advanced medical
therapies in suitable patients with class III symptoms.2
Survival after discharge from the hospital was calculated with a censor
date of December 31, 2008. For patients from England and Wales, the Na-
tional Health Service spine summary care record-tracking system was used
based on the patient’s individual National Health Service number. For pa-
tients from Scotland and Ireland, survival status was checked with the gen-
eral practitioner during the first 2 weeks of January 2009 by 2 independent
researchers from the Papworth research and development department.
Statistics
Analysis was performed with the SPSS version 13.0 statistical software
package (SPSS, Inc, Chicago, Ill). Continuous variables are described as the
mean  standard deviation or median  interquartile range and compared
by using Student’s t test or the Mann–Whitney U test, as appropriate. Cat-
egorical data are expressed as proportions and compared by using the c2
test. Follow-up over time was assessed by using repeated-measures analysis
of variance or the Friedman test, as appropriate. Estimation of cumulative
survival was performed by using the Kaplan–Meier method and compared
with the log-rank test.
RESULTS
During the period from the start of the program in 1997
and December 2007, 314 patients underwent pulmonary
endarterectomy at Papworth hospital, survived to hospital
discharge, and completed follow-up. Full hemodynamic
data were available for 306 patients at 3 months (97.4%
complete). The mean age of the study population was 55
years (range, 17–81 years), and 54.3% were male.
Thirty-one percent of patients had an mPAP of 30 mm Hg
or greater at 3 months after pulmonary endarterectomy.
The NYHA class for the whole cohort at baseline and
follow-up is shown in Figure 1, A, and the hemodynamic
data are shown in Table 1. As expected, by 3 months after
pulmonary endarterectomy, there was a significant reduction
in mPAP (48  12 to 26  10 mm Hg, P< .001) and PVR
(805 365 to 301 232 dynes $ s1 $ cm5, P<.001). Car-
diac index was increased significantly for the whole group
(2.0  0.7 to 2.5  0.5 L $ min1 $ m2, P< .001).
Patients in group 1 enjoyed significantly better exercise
capacity and improved symptoms compared with those in
group 2 (Table 2 and Figure 1, B). The postoperative
6-minute walk distance was significantly greater in groupery c February 2011
FIGURE 1. A, New York Heart Association class at baseline and 3 and 12
months after pulmonary endarterectomy for the whole cohort. B, New York
Heart Association class at baseline and 3 and 12 months after pulmonary
endarterectomy for each group. Group 1, Mean pulmonary artery pressure
of less than 30 mm Hg; group 2, mean pulmonary artery pressure of
30 mm Hg or greater.
TABLE 1. Hemodynamic data for the cohort (median ± interquartile
range)
Preoperative
(n ¼ 314) 3 mo (n ¼ 306) P value
mPAP (mm Hg) 48  12 26  10 <.001
PVR (dynes $ s1 $ cm5) 805  365 301  232 <.001
CI (L $ min1 $ m2) 2.0  0.7 2.5  0.5 <.001
SMWD (m) 269  119 367  108 <.001
Patients underwent right heart catheterization at 3 months as part of routine follow-up.
Eight patients did not have full right heart catheterization data at 3 months. mPAP,
Mean pulmonary artery pressure; PVR, pulmonary vascular resistance; CI, cardiac
index; SMWD, 6-minute walk distance.
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D1 at 3 months, as well as at 12 months (Figure 2). Of interest,
the only preoperative parameter found to be different
between the groups was 6-minute walk distance, which
was lower in group 2 even at baseline (Figure 2). After the
3-month hemodynamic assessment and clinical review, 24
patients were started on targeted medical therapy, 7.6% of
the cohort. All these patients were in group 2, and therefore
25% of those with residual PH required treatment. TheFIGURE 2. Six-minute walk test distance in meters. mPAP, Mean pulmo-
nary artery pressure.
The Journal of Thoracic and Cadisease type, classified intraoperatively, on a subset of 135
patients after 2004 is shown in Table 3.
mPAP, cardiac index, and PVR were not different
between groups 1 and 2 preoperatively. However, the
preoperative 6-minute walk distance was lower in group
2 (247  121 vs 282  121 m, P ¼ .03); this was the only
difference between the groups.
During the period of this study, 368 patients with CTEPH
were treated by means of pulmonary endarterectomy. Fifty-
four patients died before the 3-month assessment, and the
surviving 314 patients make up the study cohort. Early (be-
fore 3 months) mortality was era dependent: 25% (29/114
patients) for the years 1997-2002 and 2.7% (3/110 patients)
for 2006-2007. Conditional survival after discharge from the
hospital at a mean follow-up of 4.2 years was 92.6% and
was not different between groups (92.7% for group 1 vs
92.6% for group 2, P ¼ .36, Figure 3). Survival for all pa-
tients, including deaths in the first 3-month period, was
76% at 5 years, with a conditional survival of 90%. Survival
status at the censor date could not be confirmed in 2 patients,
and therefore follow-up was 99% complete. No patients un-
derwent lung transplantation after pulmonary endarterec-
tomy, but 1 patient underwent a redo endarterectomy for
recurrent disease 3 years after the original procedure.
DISCUSSION
We have reported that the excellent early results of pulmo-
nary endarterectomy surgery are sustained by 1 year.17 We
have now extended this work by examining the effect ofTABLE 2. Comparison between patients without (group 1) or with
(group 2) residual pulmonary hypertension (median ± interquartile
range)
3 mo after operation
Group 1
(n ¼ 210)
Group 2
(n ¼ 96) P value
mPAP (mm Hg) 20  5 38  8 <.001
PVR (dynes $ s1 $ cm5) 181  88 541  250 <.001
CI (L $ min1 $ m2) 2.5  0.6 2.5  0.62 NS
SMWD (m) 386  106 337  97 <.001
NYHA class I or II (n) 88.1% (170/193) 68.9% (62/90) <.001
mPAP, Mean pulmonary artery pressure; PVR, pulmonary vascular resistance; CI, car-
diac index; NS, not significant; SMWD, 6-minute walk distance; NYHA, New York
Heart Association.
rdiovascular Surgery c Volume 141, Number 2 385
TABLE 3. Comparison of disease type at the time of the operation by
means of Jamieson classification
Disease type Group 1 (n ¼ 86) Group 2 (n ¼ 49) P value
1 41 (48%) 15 (31%) NS
2 38 (44%) 22 (45%) NS
3 7 (8%) 10 (20%) NS
4 0 (0%) 2 (4%) NS
Data were only available for 135 patients.22 NS, Not significant.
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Dpotentially significant residual PH on symptom status, func-
tional capacity, and intermediate survival for all of the
United Kingdom patients surviving pulmonary endarterec-
tomy from the start of our series in 1997 to the end of
2007. As expected, patients with normalized hemodynamics
(group 1) had minimal symptoms and better exercise capac-
ity. However, those with residual PH by our definition
(group 2) still showed significant improvement compared
with their preoperative status. Importantly, we have con-
firmed that both groups had equally good survival at 5 years.
A significant implication of these results is that pulmonary
endarterectomy should be considered in all patients with
CTEPH, including those with severely increased PH, be-
cause as long as the PVR can be reduced enough to survive
the perioperative period, the prognosis is very good, even in
those in whom hemodynamics do not fully normalize.
Although the majority of patients are ‘‘cured’’ by pulmo-
nary endarterectomy and regain normal pulmonary pres-
sures, residual PH might be thought of as an inevitable
consequence of the 2-compartment model of CTEPH.18-20
The finding from the Vienna group that 92% of patients
with ‘‘associated medical conditions’’ (splenectomy,
indwelling venous catheters, and inflammatory diseases)
had residual PH after pulmonary endarterectomy5 substanti-
ates this hypothesis because many of these medical condi-FIGURE 3. Effect of residual pulmonary hypertension on survival after
hospital discharge. mPAP, Mean pulmonary artery pressure.
386 The Journal of Thoracic and Cardiovascular Surgtions are associated with a more distal type of disease.
However, it could also be argued that residual PH is a com-
plication of inadequate surgical clearance, and every effort
should be made to ensure a complete clearance at the time
of the operation for patients to enjoy the best result of pulmo-
nary endarterectomy. With increasing institutional and sur-
gical experience, most centers report improved in-hospital
survival as case volume increases. Little is known about re-
sidual PH after pulmonary endarterectomy surgery because
only 2 other centers have reported detailed outcomes in this
way.5,8 Bonderman and associates5 reported an incidence of
35% by 1 year, and Corsico and colleagues8 reported an in-
cidence of 24% at 4 years, albeit in smaller series with dif-
ferent definitions at later time points. Taken together with
our data, the evidence suggests that up to one third of pa-
tients might be affected despite apparently successful pul-
monary endarterectomy surgery. It is known that operative
mortality is reduced with increasing institutional experience,
and one might expect a similar reduction is residual PH in
surviving patients. However, it could also be argued that
more experienced centers are more likely to accept patients
with worse hemodynamics and more distal disease with the
inevitable consequence of some residual PH.23,24
A classification scheme for thromboembolic disease was
proposed based on operative findings.23 This scheme has
been adopted by many centers, including our own. Unfortu-
nately, we did not start recording this information prospec-
tively into the database until 2004, and therefore
information was not available on the whole cohort. As might
be expected, there was a trend suggesting that more patients
in group 2 had distal (type 3) disease.
The results presented in this article suggest that residual
PH (by our definition) after pulmonary endarterectomy sur-
gery does not have a significant effect on survival. This ini-
tially appears counterintuitive because the degree of PH in
patients with CTEPH at presentation correlates with sur-
vival.1 A similar apparent anomaly is also sometimes ob-
served in trials of drug treatment in patients with PH,
when a significant improvement is observed in one outcome
measure in response to treatment but does not translate into
similar improvements in a second end point, despite both end
points correlating at baseline.16 It might be that the absolute
pulmonary artery pressure, cardiac output, or walk distance
greater or less than a threshold value is more important
than the change in response to treatment. It is also important
to recognize that the majority of patients with residual PH in
this study, even by our enhanced definition, had only mod-
estly increased pulmonary pressures (mean for group 2, 38
mm Hg), and in addition, some were receiving targeted pul-
monary vasodilator therapy. It is likely that improved medi-
cal care might be contributing to the unexpectedly good
results in those with residual PH. At present, despite the pub-
lication of the Bosentan Effects in Inoperable Forms of
Chronic Thromboembolic Pulmonary Hypertension study,ery c February 2011
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must be viewed with caution until more data are available
and larger trials have been completed. However, if the
dual-compartment model of CTEPH is correct, one might
expect an improvement with targeted therapy in patients after
pulmonary endarterectomy. It also highlights the importance
of structured follow-up and reassessment so that residual PH
can be diagnosed and appropriate treatment instituted.16,25
In conclusion, we confirm that pulmonary endarterectomy
is a remarkably good treatment for patients with CTEPH,
and even if significant residual PH is present, patients leav-
ing the hospital alive have a very good medium-term sur-
vival. The best functional outcome is obtained in patients
with completely normalized hemodynamics after surgical
intervention.
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